Current clinical trials evaluate targeting of ROR1/2 in breast cancer as a novel therapeutic approach by using CAR-T cells or the monoclonal antibody cirmtuzumab directed against ROR1 [3]. The gene discussed is ROR1; the disease is breast carcinoma.